US Patent Issued to DIZAL (JIANGSU) PHARMACEUTICAL on Sept. 1 for "Anti-FGFR2B antibodies" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 1 -- United States Patent no. 12,723,091, issued on Sept. 1, was assigned to DIZAL (JIANGSU) PHARMACEUTICAL Co. LTD. (Shanghai).

"Anti-FGFR2B antibodies" was invented by Mei Wang (Shanghai), Qiuli Guo (Shanghai), Yu Bai (Shanghai), Zhenfan Yang (Shanghai) and Xiaolin Zhang (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are anti-FGFR2b antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof."

The patent was filed on Dec. 23, 2020, under Application No. 17/788,733.

*For further information, including images, charts and tables, please visit: http://patft.uspto.go...